General Information
NeuroBo NASH DA1241_NASH_IIa
A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA-1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).
| Protocol | DA1241_NASH_IIa |
|---|---|
| Identifier | |
| UID | f43faec6-a3fd-41d6-aa40-53005d055b75 |
| Status | Done - Archived |
| Phase | 2a |
| Category | NASH / Adult |
| Launch Year | 0 |
| NCT Number | - |
| Created | 2023-07-17 15:39 |
| Last Updated | 2025-01-07 15:36 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2024-04-19 | No |
| Enrollment Open | 2023-10-19 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2023-10-02 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2025-02-13 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Armendariz, Rocio | RArmendariz | No |
| Regulatory | - | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | NeuroBo Pharmaceuticals, Inc |
|---|---|
| Division | NeuroBo Pharmaceuticals, Inc |
| Team | NeuroBo Pharmaceuticals, Inc |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Fortrea Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
